当前位置: 首页 > 期刊 > 《医学信息》 > 201433
编号:13665881
HE4检测在卵巢癌早期诊断及鉴别诊断中的应用价值(2)
http://www.100md.com 2014年8月20日 陆泓 邱云芬 刘春花
第1页

    参见附件。

     综上所述,HE4作为一种新的卵巢癌肿瘤标记物,对卵巢癌的检测与CAl25相当甚至优于cAl25,HE4与CA125的联合检测提高了卵巢上皮癌诊断的准确性,有助于评估盆腔包块患者卵巢癌的风险性,在卵巢癌的早期诊断及鉴别诊断上具有很高的应用价值。当然,这个结论仍需临床大样本的研究来进一步证实。

    参考文献:

    [1]Whitehouse C, Solomon E. Current status of the molecular characterization of the ovarian cancer antigen CA125 and implications for its use in clinical screening[J]. Gynecol Oncol, 2003, 88: S152-157.

    [2]刘润幸.使用SPSS 作多变量观察值的ROC 曲线分析[J].中国公共卫生,2003,19:1151-1152.

    [3]Bast Jr RC.Status of tumour markers in ovarian screening[J].J Clin Oncol,2003,21(10):200-205.

    [4]Hellstrom I,Raycraft J,Hayden-Ledbetter M,et a1.The HE4(WFDC2)protein is a biomarker for ovarian carcinoma[J].Cancer Res,2003,63(13):3695-3700.

    [5]Ruggeri G,Bandiera E,Zanotti L,et al.HE4 and epithelial ovarian cancer :comparison and clinical evaluation of two immunoassays and a combination aigorithm[J].Clin Chim Acta ,2011,412(15-16):1447-1453.

    [6]Van Gorp T,Cadron I,Despierre E,et al.HE4 and CA125 as a diagnostic test in ovarian cancer:prospectivevalidation of the risk of ovarian malignancy algorithm[J].Br J Cancer,2011,104(5):863-870.

    [7]Kalapotharakos G,Asciutto C,Henic E,et al.High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer[J].J Ovarian Res,2012,5(1):20.

    [8]Moore R G,Brown A K,Miller M C,et a1.The use of multip le novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass[J].Gynecol Oncol,2008,108(2):405.

    [9]Barbieri R L. In women who have a pelvic mass Have you tried this new ovarian Ca biomarker[J].OBG Management,2010,22(4):8-12.编辑/申磊

    

您现在查看是摘要介绍页,详见PDF附件